JP2024170456A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024170456A5 JP2024170456A5 JP2024144789A JP2024144789A JP2024170456A5 JP 2024170456 A5 JP2024170456 A5 JP 2024170456A5 JP 2024144789 A JP2024144789 A JP 2024144789A JP 2024144789 A JP2024144789 A JP 2024144789A JP 2024170456 A5 JP2024170456 A5 JP 2024170456A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203183 | 2018-10-29 | ||
| EP18203183.1 | 2018-10-29 | ||
| US201862752641P | 2018-10-30 | 2018-10-30 | |
| US62/752,641 | 2018-10-30 | ||
| JP2021524345A JP2022506761A (ja) | 2018-10-29 | 2019-10-29 | ＩｇＡ抗体構築物を含む組成物および方法 |
| PCT/US2019/058648 WO2020092427A1 (en) | 2018-10-29 | 2019-10-29 | COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524345A Division JP2022506761A (ja) | 2018-10-29 | 2019-10-29 | ＩｇＡ抗体構築物を含む組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024170456A JP2024170456A (ja) | 2024-12-10 |
| JP2024170456A5 true JP2024170456A5 (enExample) | 2025-07-07 |
Family
ID=70462698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524345A Pending JP2022506761A (ja) | 2018-10-29 | 2019-10-29 | ＩｇＡ抗体構築物を含む組成物および方法 |
| JP2024144789A Pending JP2024170456A (ja) | 2018-10-29 | 2024-08-26 | ＩｇＡ抗体構築物を含む組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524345A Pending JP2022506761A (ja) | 2018-10-29 | 2019-10-29 | ＩｇＡ抗体構築物を含む組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210332131A1 (enExample) |
| EP (1) | EP3873942A4 (enExample) |
| JP (2) | JP2022506761A (enExample) |
| KR (1) | KR20210096612A (enExample) |
| CN (1) | CN113260632A (enExample) |
| AU (1) | AU2019369397A1 (enExample) |
| CA (1) | CA3118312A1 (enExample) |
| GB (1) | GB2596411B (enExample) |
| WO (1) | WO2020092427A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7607579B2 (ja) * | 2019-03-27 | 2024-12-27 | ティガティーエックス， インコーポレイテッド | 工学的に操作されたＩｇＡ抗体および使用方法 |
| EP4232052A4 (en) * | 2020-10-22 | 2025-08-20 | Actinium Pharmaceuticals Inc | COMBINATION OF RADIOMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER |
| EP4256034A4 (en) * | 2020-12-07 | 2024-11-20 | The Regents of the University of California | Innate immune cell silencing by sirp-alpha engager |
| EP4475886A4 (en) * | 2022-02-09 | 2026-03-18 | Exelixis Inc | MULTI-SPECIFIC LIAISON AGENTS AND THEIR USES |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0226878D0 (en) * | 2002-11-18 | 2002-12-24 | Univ Warwick | Antibodies |
| ES2672640T3 (es) * | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| LT2334705T (lt) * | 2008-09-26 | 2017-03-27 | Ucb Biopharma Sprl | Biologiniai produktai |
| US8758750B2 (en) * | 2009-09-15 | 2014-06-24 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-CD47 therapy for hematologic cancers |
| US20140359902A1 (en) * | 2011-12-16 | 2014-12-04 | Synthon Biopharmaceuticals B.V. | EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED |
| JP6392770B2 (ja) * | 2012-12-03 | 2018-09-19 | ノビミューン エスアー | 抗ｃｄ４７抗体およびその使用方法 |
| US20140213771A1 (en) * | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Multi-specific binding proteins |
| AU2014227638A1 (en) * | 2013-03-15 | 2015-09-17 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| NZ720353A (en) * | 2013-12-30 | 2019-12-20 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
| WO2016022971A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Sirp alpha-antibody fusion proteins |
| AU2015303135B2 (en) * | 2014-08-15 | 2021-05-20 | Merck Patent Gmbh | SIRP-alpha immunoglobulin fusion proteins |
| AU2016326423A1 (en) * | 2015-09-21 | 2018-04-26 | Erasmus University Medical Center | Anti-CD47 antibodies and methods of use |
| CN107459579B (zh) * | 2016-06-01 | 2021-09-24 | 泰州迈博太科药业有限公司 | 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用 |
| PL3507303T3 (pl) * | 2016-09-01 | 2025-12-08 | Tigatx, Inc. | Przeciwciała CD20 |
| WO2018137705A1 (en) * | 2017-01-26 | 2018-08-02 | Zai Lab (Shanghai) Co., Ltd. | Cd47 antigen binding unit and uses thereof |
| DK3658141T3 (da) * | 2017-07-24 | 2023-02-06 | Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis | Behandling af patologiske tilstande ved direkte og indirekte målretning af Sirpalpha-CD47-interaktion |
| TWI772488B (zh) * | 2017-08-08 | 2022-08-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎DLBCL病患次族群之歐比托珠單抗(obinutuzumab)治療 |
-
2019
- 2019-10-29 JP JP2021524345A patent/JP2022506761A/ja active Pending
- 2019-10-29 AU AU2019369397A patent/AU2019369397A1/en active Pending
- 2019-10-29 KR KR1020217016137A patent/KR20210096612A/ko active Pending
- 2019-10-29 EP EP19879444.8A patent/EP3873942A4/en active Pending
- 2019-10-29 CA CA3118312A patent/CA3118312A1/en active Pending
- 2019-10-29 CN CN201980087109.4A patent/CN113260632A/zh active Pending
- 2019-10-29 GB GB2107478.6A patent/GB2596411B/en active Active
- 2019-10-29 WO PCT/US2019/058648 patent/WO2020092427A1/en not_active Ceased
-
2021
- 2021-04-28 US US17/242,793 patent/US20210332131A1/en active Pending
-
2024
- 2024-08-26 JP JP2024144789A patent/JP2024170456A/ja active Pending